COVID-19: China Sinovac, Vaccine development with traditional technology: Kaoxing Biotechnology
Development of new corona vaccine:
Over 200 projects are underway worldwide.
Many of them
Messenger RNA (mRNA)
Genetically modified virus, etc.
Focus on new technologies.
Kaxing Biotechnology: (Sinovac Biotech)
The leading group in China, Sinovac uses technology that has been used for hundreds of years.
In July 2020, the final stage clinical trial of vaccine candidates was started.
The company’s vaccine candidates are
Using the inactivated new coronavirus
Let the body’s immune system learn
It’s about attacking a real virus.
Sinovac vaccine candidates:
This vaccine candidate is ahead of the others.
US modeler mRNA vaccine,
With genetically modified vaccines of British Oxfort and AstraZeneca,
It is highly likely that commercial production will begin at about the same time.
Synovac’s method:
It is based on a principle similar to Edward Jenner’s development of the world’s first smallpox vaccine using the mild cowpox virus.
It may still work, but it will be easier to use than approaches using other companies’ new technologies.
Clinical trials in Brazil:
Sinovac is awaiting the results of the Phase 3 trial, including a clinical trial in Brazil involving approximately 9,000 people.
If the test is successful, it will produce at least 300 million times a year at its own factory, and plans to outsource additional production to other companies.
Bloomberg
https://www.bloomberg.co.jp/news/articles/2020-08-24/QFJV8CT1UM1101
Coronavirus Vaccine: China’s Covid Front-Runner Uses Brute-Force Approach
Sinovac’s method
is relatively crude, relying on a similar principle to the one Edward Jenner, the 18th century British scientist sometimes called the father of immunology, employed
when he used the mild cowpox virus to perform the first-ever inoculations against smallpox.
But it just might work—and it could be easier to use than the never-before-tried approaches of other companies.
Bloomberg